Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
Priovant, a Roivant company, enrolled the first patients in the Phase 3 BEACON+ study evaluating brepocitinib for cutaneous sarcoidosis (CS), targeting approximately 140 patients globally. This Phase 3 initiation follows positive Phase 2 data where 77% of brepocitinib patients achieved the primary endpoint compared to 0% on placebo, securing FDA Breakthrough Therapy Designation for the drug in CS.
Key figures
- Drug Name
- Brepocitinib
- Phase Of Trial
- Phase 3
- Dose mg
- 45
- Site count
- 70
- Patient count
- 140
- Pdufa date dm
- end of September 2026
- Topline data year
- 2028
- Phase2 placebo rate
- 0%
- Us prevalence adults
- 40000
- Phase2 responder rate
- 77%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.